JPH10120559A - Internal liquid medicine containing taurine - Google Patents
Internal liquid medicine containing taurineInfo
- Publication number
- JPH10120559A JPH10120559A JP9212944A JP21294497A JPH10120559A JP H10120559 A JPH10120559 A JP H10120559A JP 9212944 A JP9212944 A JP 9212944A JP 21294497 A JP21294497 A JP 21294497A JP H10120559 A JPH10120559 A JP H10120559A
- Authority
- JP
- Japan
- Prior art keywords
- liquid medicine
- taurine
- isomerized sugar
- isomerized
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229960003080 taurine Drugs 0.000 title claims abstract description 20
- 239000007788 liquid Substances 0.000 title abstract description 34
- 239000003814 drug Substances 0.000 title abstract description 11
- 235000000346 sugar Nutrition 0.000 claims abstract description 34
- 229960003495 thiamine Drugs 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- 239000012669 liquid formulation Substances 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 8
- 239000005720 sucrose Substances 0.000 abstract description 8
- 239000000796 flavoring agent Substances 0.000 abstract description 5
- 235000019634 flavors Nutrition 0.000 abstract description 5
- 235000003599 food sweetener Nutrition 0.000 abstract description 5
- 239000003765 sweetening agent Substances 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001948 caffeine Drugs 0.000 abstract description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 229940109850 royal jelly Drugs 0.000 abstract description 2
- 150000005846 sugar alcohols Polymers 0.000 abstract description 2
- 239000002304 perfume Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 239000012085 test solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 sucrose Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、タウリンを配合し
た内服液剤に関する。[0001] The present invention relates to an oral solution containing taurine.
【０００２】[0002]
【従来の技術】タウリン（アミノエチルスルホン酸）は
様々な効能が知られ、近年ドリンク剤などの内服液剤に
頻繁に配合されている。また、ドリンク剤などの内服液
剤は、疲労改善、風味などの点で甘味剤の配合が必須に
なっている。2. Description of the Related Art Taurine (aminoethyl sulfonic acid) is known for its various effects and is frequently used in oral liquids such as drinks in recent years. In addition, in the case of oral liquid preparations such as drink preparations, it is essential to add a sweetener in terms of improving fatigue, flavor and the like.
【０００３】従来、内服液剤に配合する甘味剤としては
ショ糖を用いることが一般的である。しかし、タウリン
などのアミノ酸とショ糖などの糖質を配合した液剤は、
一般に経時的に褐変（溶液の褐色への変色）する。[0003] Conventionally, sucrose has generally been used as a sweetening agent to be incorporated into a liquid preparation for internal use. However, a liquid formulation containing an amino acid such as taurine and a saccharide such as sucrose,
Generally, it browns over time (discoloration of the solution to brown).
【０００４】[0004]
【発明が解決しようとする課題】内服液剤を肉体疲労時
の栄養補給の目的で服用する場合は、配合する糖質はシ
ョ糖より吸収性の良い異性化糖を用いた方が速効性の点
で好ましい。また、異性化糖は液体であることから、液
剤の製造が容易である点からも内服液剤に配合する糖質
としてはショ糖よりも異性化糖の方が好ましい。SUMMARY OF THE INVENTION When taking an oral liquid for nutritional supplementation during physical fatigue, it is more effective to use isomerized sugar, which is more absorbable than sucrose, as a carbohydrate to be blended. Is preferred. In addition, since isomerized sugar is a liquid, isomerized sugar is more preferable than sucrose as a saccharide to be mixed into an internal liquid solution from the viewpoint of easy production of a liquid preparation.
【０００５】しかし、通常の異性化糖を配合したタウリ
ン配合液剤は特に褐変しやすいため、タウリンを配合し
た液剤に異性化糖を用いるのは困難であった。[0005] However, it is difficult to use isomerized sugar in a liquid formulation containing taurine, because a liquid formulation containing taurine containing ordinary isomerized sugar is particularly liable to brown.
【０００６】さらに、一般的に内服液剤は配合薬として
ビタミンＢ１類（チアミンもしくはその塩、フルスルチ
アミンなど）を配合することが多いが、通常の異性化糖
を用いたタウリン配合液剤にビタミンＢ１類を配合する
と、さらに褐変が促進されることも見出した。Further, in general, oral liquid preparations often contain vitamin B1 (thiamine or a salt thereof, fursultiamine, etc.) as a compounding drug. However, vitamin B1 is usually added to taurine compounding liquid using ordinary isomerized sugar. It was also found that browning was further promoted when the compounds were blended.
【０００７】本発明は、タウリンおよび異性化糖を配合
した液剤の褐変軽減を目的とする。An object of the present invention is to reduce browning of a solution containing taurine and isomerized sugar.
【０００８】[0008]
【課題を解決するための手段】本発明者らは鋭意研究し
た結果、タウリンを配合した液剤に、灰分が０．００１
重量％以下の異性化糖を配合すると、通常の異性化糖を
配合した液剤と比較して、液剤の褐変が大幅に軽減さ
れ、甘味剤として従来汎用されるショ糖を用いた液剤と
褐変の度合いがほぼ同等であることを見いだし本発明を
完成した。Means for Solving the Problems As a result of intensive studies, the present inventors have found that a solution containing taurine has an ash content of 0.001%.
When the isomerized saccharide is blended in an amount of not more than 10% by weight, the browning of the liquid is significantly reduced as compared with the liquid containing normal isomerized saccharide. The inventors have found that the degrees are almost equal and completed the present invention.
【０００９】すなわち本発明は、灰分が０．００１重量
％以下の異性化糖を配合することを特徴とするタウリン
配合内服液剤である。[0009] That is, the present invention is an internal liquid containing taurine, which is characterized by containing isomerized sugar having an ash content of 0.001% by weight or less.
【００１０】[0010]
【発明の実施の形態】本発明において灰分とは、物質を
燃焼した後に残った灰のことである。灰分の測定方法は
異性化糖を燃焼した後の残存物の重量を測定することに
より算出される。本発明で用いる異性化糖はその灰分が
異性化糖全体の０．００１重量％以下のものである。ま
た、灰分が０．０００６重量％以下のものが褐変低減の
点でさらに好ましい。BEST MODE FOR CARRYING OUT THE INVENTION The ash in the present invention is ash remaining after burning a substance. The method of measuring the ash content is calculated by measuring the weight of the residue after burning the isomerized sugar. The isomerized sugar used in the present invention has an ash content of 0.001% by weight or less of the whole isomerized sugar. Further, those having an ash content of 0.0006% by weight or less are more preferable in terms of reducing browning.
【００１１】本発明に使用する異性化糖は市販される異
性化糖を、イオン交換樹脂または活性炭の濾過を繰り返
しての精製、分取ＨＰＬＣ法による精製などにより得ら
れるが、製造時に灰分が少ない異性化糖を製造して使用
することも可能である。The isomerized saccharide used in the present invention can be obtained by purifying a commercially available isomerized saccharide by repeatedly filtering an ion-exchange resin or activated carbon, purifying by a preparative HPLC method, etc. It is also possible to produce and use isomerized sugars.
【００１２】本発明において、タウリンの配合量は内服
液剤として通常使用される範囲であり、好ましくは液剤
全体の０．０２〜４．０ｗ／ｖ％である。また、異性化
糖の配合量は、風味の点から液剤全体の５〜４０ｗ／ｖ
％が好ましい。In the present invention, the amount of taurine is in the range usually used as a liquid preparation for internal use, and is preferably 0.02 to 4.0 w / v% of the whole liquid preparation. The amount of the isomerized sugar is 5 to 40 w / v of the whole liquid in terms of flavor.
% Is preferred.
【００１３】本発明の液剤は、風味の点からｐＨ２．０
〜６．０の範囲が好ましい。特に好ましくはｐＨ２．５
〜４．５である。The liquid preparation of the present invention has a pH of 2.0 from the viewpoint of flavor.
The range of -6.0 is preferable. Particularly preferably, pH 2.5
４4.5.
【００１４】さらに、本発明では、タウリンおよびビタ
ミンＢ１類を同時に配合した液剤においても灰分が０．
００１重量％以下の異性化糖を用いれば、褐変は軽度で
あることが判った。Further, according to the present invention, the ash content of a liquid preparation containing taurine and vitamin B1 at the same time is also reduced to 0.1.
The browning was found to be mild when less than 001% by weight of the isomerized sugar was used.
【００１５】本発明の液剤は酸を同時に配合すると風味
の点で好ましい。そのときの酸としてはクエン酸、リン
ゴ酸、酒石酸、コハク酸、乳酸、酢酸、マレイン酸、グ
ルコン酸、アスパラギン酸、アジピン酸、グルタミン
酸、フマル酸、リン酸、塩酸、酢酸などをあげることが
できるが、特に好ましいものとして酒石酸、クエン酸ま
たはリンゴ酸をあげることができる。The liquid preparation of the present invention is preferably mixed with an acid from the viewpoint of flavor. Examples of the acid at that time include citric acid, malic acid, tartaric acid, succinic acid, lactic acid, acetic acid, maleic acid, gluconic acid, aspartic acid, adipic acid, glutamic acid, fumaric acid, phosphoric acid, phosphoric acid, hydrochloric acid, acetic acid and the like. However, particularly preferred are tartaric acid, citric acid and malic acid.
【００１６】本発明の液剤は、服用感の改善のために甘
味剤を加えることもできる。甘味剤としては、ショ糖、
果糖、ブドウ糖、麦芽糖、トレハロース、パラチノー
ス、マルチトール、ソルビトール、パラチニット、エリ
スリトール、キシリトール、ステビア、ソーマチンなど
があげられる。The liquid preparation of the present invention may further contain a sweetening agent for improving the feeling of taking. As sweeteners, sucrose,
Fructose, glucose, maltose, trehalose, palatinose, maltitol, sorbitol, palatinit, erythritol, xylitol, stevia, thaumatin and the like.
【００１７】本発明の液剤は液剤製造の通常の方法によ
り製造することができる。The liquid preparation of the present invention can be produced by a usual method for producing liquid preparations.
【００１８】本発明の液剤には、上記成分の他、通常液
剤に用いることの可能な成分、例えば各種ビタミン（ビ
タミンＢ２、ビタミンＢ３、ビタミンＢ５、ビタミンＢ
６、ビタミンＢ１２、ビタミンＡ、ビタミンＤ２、ビタ
ミンＢ３、ビタミンＥ、ビタミンＰ、ビタミンＫ１、ビ
タミンＨ、ビタミンＦ、ビタミンＵなど）もしくはビタ
ミン誘導体、アミノ酸（Ｌ−アスパラギン酸、Ｌ−アル
ギニン、トリプトファン、リジンなど）、生薬（ムイラ
プアマ、ニンジン、ジオウなど）、カフェイン、ローヤ
ルゼリー、多価アルコール（プロピレングリコールな
ど）、香料、保存剤などを本発明の効果を損なわない範
囲で配合することができる。In the liquid preparation of the present invention, in addition to the above-mentioned components, components which can be usually used in liquid preparations, for example, various vitamins (vitamin B2, vitamin B3, vitamin B5, vitamin B5)
6. Vitamin B12, Vitamin A, Vitamin D2, Vitamin B3, Vitamin E, Vitamin P, Vitamin K1, Vitamin H, Vitamin F, Vitamin U, or vitamin derivatives, amino acids (L-aspartic acid, L-arginine, tryptophan) Lysine, etc.), crude drugs (such as muirapuama, carrot, and siodium), caffeine, royal jelly, polyhydric alcohols (such as propylene glycol), fragrances, and preservatives can be added as long as the effects of the present invention are not impaired.
【００１９】[0019]
【発明の効果】本発明により、タウリン配合液剤に異性
化糖を使用しても褐変しない液剤を提供することが可能
になった。According to the present invention, it has become possible to provide a liquid preparation which does not brown even when isomerized sugar is used in the liquid preparation containing taurine.
【００２０】[0020]
【実施例】以下、実施例および試験例をあげて本発明を
さらに詳細に説明する。The present invention will be described below in more detail with reference to examples and test examples.
【００２１】実施例１の異性化糖は市販品を分取用ＨＰ
ＬＣにより精製したものであり、比較例１〜５の異性化
糖は市販品をそのまま使用したものである。なお、異性
化糖の灰分は燃焼残存物の重量を電子天秤（メトラー社
製）で測定し算出した。The isomerized saccharide of Example 1 was prepared by using a commercially available HP
The product was purified by LC, and the isomerized saccharides of Comparative Examples 1 to 5 were directly used as commercial products. The ash content of the isomerized sugar was calculated by measuring the weight of the combustion residue using an electronic balance (manufactured by Mettler).
【００２２】実施例１ ビタミンＢ１硝酸塩 ３ｍｇ タウリン ７５０ｍｇ クエン酸ナトリウム １４０ｍｇ 異性化糖（灰分０．０００６％） １０７００ｍｇ クエン酸（ｐＨ調節剤） 適量 精製水 全５０ｍｌ 上記各成分を混合溶解し、クエン酸でｐＨ２．８に調節
後８０℃で３０分間滅菌して、試験溶液を得た。Example 1 Vitamin B1 nitrate 3 mg Taurine 750 mg Sodium citrate 140 mg Isomerized sugar (ash content 0.0006%) 10700 mg Citric acid (pH regulator) Appropriate amount Purified water 50 ml Mix and dissolve the above components and use citric acid. After adjusting the pH to 2.8, the solution was sterilized at 80 ° C. for 30 minutes to obtain a test solution.
【００２３】比較例１ 実施例１の異性化糖を灰分が０．００２１％の異性化糖
に変えた処方で同様の方法により試験溶液を得た。Comparative Example 1 A test solution was obtained in the same manner as in Example 1, except that the isomerized saccharide was replaced with an isomerized saccharide having an ash content of 0.0021%.
【００２４】比較例２ 実施例１の異性化糖を灰分が０．００７４％の異性化糖
に変えた処方で同様の方法により試験溶液を得た。Comparative Example 2 A test solution was obtained in the same manner as in Example 1, except that the isomerized sugar was replaced with the isomerized sugar having an ash content of 0.0074%.
【００２５】比較例３ 実施例１の異性化糖を灰分が０．００２９％の異性化糖
に変えた処方で同様の方法により試験溶液を得た。Comparative Example 3 A test solution was obtained in the same manner as in Example 1 except that the isomerized sugar was replaced with the isomerized sugar having an ash content of 0.0029%.
【００２６】比較例４ 実施例１の異性化糖を灰分が０．００３９％の異性化糖
に変えた処方で同様の方法により試験溶液を得た。Comparative Example 4 A test solution was obtained in the same manner as in Example 1 except that the isomerized sugar was replaced with the isomerized sugar having an ash content of 0.0039%.
【００２７】比較例５ 実施例１の異性化糖を灰分が０．００１９％の異性化糖
に変えた処方で同様の方法により試験溶液を得た。Comparative Example 5 A test solution was obtained in the same manner as in Example 1 except that the isomerized sugar was replaced with an isomerized sugar having an ash content of 0.0019%.
【００２８】比較例６ 実施例１の異性化糖をショ糖８０００ｍｇに変えた処方
で同様の方法により試験溶液を得た。Comparative Example 6 A test solution was obtained in the same manner as in Example 1 except that the isomerized sugar was changed to 8000 mg of sucrose.
【００２９】試験例１ 実施例１および比較例１〜６で得られた対照用試験用液
を、６５℃に保存して７日および１４日時の透光度を４
００ｎｍおよび４５０ｎｍで測定した。結果を表１に示
した。Test Example 1 The control test liquids obtained in Example 1 and Comparative Examples 1 to 6 were stored at 65 ° C. and had a light transmittance of 4 on the 7th and 14th days.
Measured at 00 nm and 450 nm. The results are shown in Table 1.
【００３０】[0030]
【表１】 [Table 1]
【００３１】試験例から明らかなように、灰分の少ない
異性化糖を使用した処方（実施例１）はショ糖を用いた
場合とほぼ同等程度まで褐変が軽減できた。As is clear from the test examples, the formulation using the isomerized sugar containing less ash (Example 1) was able to reduce the browning to almost the same level as the case using sucrose.
Claims (2)
を配合することを特徴とするタウリン配合内服液剤。1. An oral liquid formulation containing taurine, which contains an isomerized sugar having an ash content of 0.001% by weight or less.
を配合することを特徴とするビタミンＢ１類およびタウ
リンを配合した内服液剤。2. An oral solution containing vitamin B1 and taurine, characterized by containing isomerized sugar having an ash content of 0.001% by weight or less.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9212944A JPH10120559A (en) | 1996-08-26 | 1997-08-07 | Internal liquid medicine containing taurine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22365796 | 1996-08-26 | ||
| JP8-223657 | 1996-08-26 | ||
| JP9212944A JPH10120559A (en) | 1996-08-26 | 1997-08-07 | Internal liquid medicine containing taurine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10120559A true JPH10120559A (en) | 1998-05-12 |
Family
ID=26519523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9212944A Pending JPH10120559A (en) | 1996-08-26 | 1997-08-07 | Internal liquid medicine containing taurine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10120559A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11322609A (en) * | 1998-05-14 | 1999-11-24 | Taisho Pharmaceut Co Ltd | Formulated liquid preparation of vitamin b1 |
-
1997
- 1997-08-07 JP JP9212944A patent/JPH10120559A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11322609A (en) * | 1998-05-14 | 1999-11-24 | Taisho Pharmaceut Co Ltd | Formulated liquid preparation of vitamin b1 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4726269B2 (en) | Oral solution | |
| JP4051717B2 (en) | Biotin-containing oral solution | |
| JP5283676B2 (en) | Method for producing collagen peptide-containing composition | |
| KR20020037065A (en) | Sweetener compositions with high degree of sweetness having improved sweetness, corrigents and utilization thereof | |
| JP4955287B2 (en) | Paeoniflorin-containing jelly preparation | |
| JP3805646B2 (en) | Pharmaceutical solution | |
| JP2006045216A (en) | Zinc-containing composition for oral administration | |
| JP4403590B2 (en) | Vitamin B1 combination liquid | |
| JPH10120559A (en) | Internal liquid medicine containing taurine | |
| JP4013267B2 (en) | Oral solution | |
| JP4206506B2 (en) | Solution containing vitamin B1 | |
| KR100254107B1 (en) | Stable liquid preparation of complex vitamin for internal use | |
| JPH10287551A (en) | Liquid agent for internal use improved in unpleasant flavor of amino acid | |
| JP4789292B2 (en) | Oral solution with improved flavor | |
| JPH054921A (en) | Vitamin b-containing oral solution agent | |
| JP6431635B1 (en) | Beverage and method for producing the same | |
| JPWO2011148794A1 (en) | Dimemorphan-containing oral solution | |
| JPH10265369A (en) | Liquid agent for internal use having improved taste | |
| JPH1179997A (en) | Liquid preparation formulating vitamin b1 therein | |
| JP5011776B2 (en) | Copper compound composition | |
| JP2016123291A (en) | Sourness masking agent | |
| JP2001131070A (en) | Riboflavin-formulated liquid composition | |
| JP4228403B2 (en) | Solution containing vitamin B1 | |
| JPH1036252A (en) | Oral liquid medicine combined with belladonna (total) alkaloid | |
| JP2002322062A (en) | Liquid preparation for oral administration |